-
Vonn to provide injury update as Milan-Cortina Olympics near
-
France summons Musk for 'voluntary interview', raids X offices
-
Stocks mostly climb as gold recovers
-
US judge to hear request for 'immediate takedown' of Epstein files
-
Russia resumes large-scale strikes on Ukraine in glacial temperatures
-
Fit-again France captain Dupont partners Jalibert against Ireland
-
French summons Musk for 'voluntary interview' as authorities raid X offices
-
IOC chief Coventry calls for focus on sport, not politics
-
McNeil's partner hits out at 'brutal' football industry after Palace move collapses
-
Proud moment as Prendergast brothers picked to start for Ireland
-
Germany has highest share of older workers in EU
-
Teen swims four hours to save family lost at sea off Australia
-
Ethiopia denies Trump claim mega-dam was financed by US
-
Norway crown princess's son pleads not guilty to rapes as trial opens
-
Russia resumes strikes on freezing Ukrainian capital ahead of talks
-
Malaysian court acquits French man on drug charges
-
Switch 2 sales boost Nintendo profits, but chip shortage looms
-
China to ban hidden car door handles, setting new safety standards
-
Switch 2 sales boost Nintendo results but chip shortage looms
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Russia resumes strikes on freezing Ukrainian capital
-
'Way too far': Latino Trump voters shocked by Minneapolis crackdown
-
England and Brook seek redemption at T20 World Cup
-
Coach Gambhir under pressure as India aim for back-to-back T20 triumphs
-
'Helmets off': NFL stars open up as Super Bowl circus begins
-
Japan coach Jones says 'fair' World Cup schedule helps small teams
-
Equities and precious metals rebound after Asia-wide rout
-
Do not write Ireland off as a rugby force, says ex-prop Ross
-
Winter Olympics 2026: AFP guide to Alpine Skiing races
-
Winter Olympics to showcase Italian venues and global tensions
-
Buoyant England eager to end Franco-Irish grip on Six Nations
-
China to ban hidden car door handles in industry shift
-
Sengun leads Rockets past Pacers, Ball leads Hornets fightback
-
Waymo raises $16 bn to fuel global robotaxi expansion
-
Netflix to livestream BTS comeback concert in K-pop mega event
-
Rural India powers global AI models
-
US House to vote Tuesday to end shutdown
-
Equities, metals, oil rebound after Asia-wide rout
-
Bencic, Svitolina make history as mothers inside tennis top 10
-
Italy's spread-out Olympics face transport challenge
-
Son of Norway crown princess stands trial for multiple rapes
-
Side hustle: Part-time refs take charge of Super Bowl
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Faced with Trump, Pope Leo opts for indirect diplomacy
-
NFL chief expects Bad Bunny to unite Super Bowl audience
-
Australia's Hazlewood to miss start of T20 World Cup
-
Bill, Hillary Clinton to testify in US House Epstein probe
-
Cuba confirms 'communications' with US, but says no negotiations yet
-
Iran orders talks with US as Trump warns of 'bad things' if no deal reached
-
From 'watch his ass' to White House talks for Trump and Petro
Cannabis extract relieves chronic back pain: high-quality trial
A specially developed cannabis extract relieves chronic lower back pain, according to a clinical trial published Wednesday that experts are calling the first high-quality evidence that something in the cannabis plant can treat pain.
Lower back pain is the leading cause of disability worldwide, affecting more than half a billion people, according to the World Health Organization.
But drugs for chronic back pain are limited to common painkillers such as ibuprofen, which can have serious side effects when used long-term, or highly addictive and potentially dangerous opioids.
In recent years, an expanding cannabis industry has claimed that a range of marijuana or cannabidiol (CBD) products can help with pain, but researchers have warned that the quality of evidence actually showing this has been low.
On Wednesday, a large placebo-controlled, phase 3 clinical trial -- which is considered the gold standard for researching medical drugs -- testing a cannabis extract was published in the journal Nature Medicine.
The trial involved more than 800 people with chronic lower back pain who did not get relief from non-opioid drugs.
After 12 weeks of taking either the cannabis extract called VER-01 or a placebo, participants were asked to report their pain level on a 10-point scale.
Those taking the extract reported a 1.9-point reduction in pain, compared to 0.6 for those on the placebo.
After six months, participants taking the extract said their pain had decreased by a higher 2.9 points.
They also reported better sleep, physical function and quality of life, according to the study.
Each dose of VER-01 contains 2.5 milligrammes of THC, the main active ingredient in marijuana.
Nothing suggested that the extract was addictive or caused serious side effects, the study said. The most common side effects were short-term dizziness, sleepiness, dry mouth and some nausea -- though they decreased over time.
The study's lead author Matthias Karst, a professor of pain medicine at Hannover Medical School in Germany, told AFP that "no feelings of (being) high" were observed during the trial.
- 'As good as it gets' -
Andrew Moore, a former pain researcher at Oxford University not involved in the study, said the "terrific" trial was "about as good as it gets".
"The trial is the first that shows good quality evidence that something in the cannabis plant can be helpful for pain," he told AFP.
But Moore also urged caution about claims that the extract was not addictive, warning that in the past, such statements have later turned out to be incorrect.
Most cannabis products vary widely in potency, purity and other factors which make them difficult for doctors to safely prescribe, Karst said.
The VER-01 strain has been specifically developed to obtain approval by medical authorities and then be prescribed for chronic pain, he added.
This means the study is not "proof that all cannabis/CBD products would be helpful in the same way," Karst emphasised.
Jan Vollert, a pain researcher at Exeter University not involved in the study, also stressed the difference between this "very specific substance" and regular marijuana.
"Smoking cannabis and taking VER-01 are probably as similar as eating hazelnuts and eating Nutella: they might share a similar basis, but they just are not comparable," he said.
L.AbuTayeh--SF-PST